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Abstract  
Introduction 
Over recent years our understanding of DNA damage repair and defects associated with its 
various pathways has evolved. This has led to an expansion of the potential target population 
for therapies attempting to exploit DNA damage repair deficiencies across multiple solid 
tumour types.  Gastric cancer has recently been identified as a tumour type where a subgroup 
of patients demonstrates deficiencies in the homologous recombination DNA repair pathway. 
This may provide a novel treatment approach for this poor prognosis disease. 
Area Covered 
This review seeks to provide an overview of DNA damage repair and how this has been 
targeted to date in other tumour types, particularly in ovarian and prostate cancer, exploiting 
the concept of synthetic lethality. This is followed by a discussion of how deficiencies in 
homologous recombination may be identified across different tumour types and then focuses 
on recent progress in targeting DNA repair deficiencies in gastric cancer, having outlined the 
current treatment paradigm for gastric cancer and explained the urgent unmet need for novel 
therapies.   
Expert Opinion 
Gastric cancer remains a difficult malignancy to treat and the possibility of targeting deficient 
DNA repair in a subgroup of patients with this disease is an exciting prospect. Future 
combinations with immunotherapy and radiotherapy are also appealing and appear to have a 
sound biological rationale. However, much work remains to be done to understand the 
D
ow
nl
oa
de
d 
by
 [K
ate
 Y
ou
ng
] a
t 0
6:4
5 0
4 A
ug
us
t 2
01
6 
3 
 
significance of the various genetic and epigenetic alterations involved, to elucidate the 
optimum predictive signatures or biomarkers and how they should be obtained and to 
consider means of overcoming treatment resistance. 
Keywords 
Gastric Adenocarcinoma 
DNA Damage Repair  
Homologous Recombination Deficiency (HRD) 
BRCAness 
Synthetic Lethality 
PARP inhibitor 
Ataxia Telangiectasia Mutated (ATM) 
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Article Highlights Box  
• Developments in recent years have greatly expanded our understanding of DNA 
damage repair pathways and of defects affecting these pathways. 
• Deficiencies in Homologous Recombination (HR) are seen across multiple tumour 
types, including gastric cancer, and various signatures have been proposed as a means 
to detect these deficiencies including multi-gene signatures, structural rearrangement 
signatures and transcriptional signatures. 
• In gastric cancer dysfunction or loss of ATM protein appears to be an important cause 
of HRD and may be associated with microsatellite instability (MSI) 
• The phase II Study 39 reported an improvement in overall survival in the second line 
treatment of advanced gastric cancer with paclitaxel in combination with the PARP 
inhibitor olaparib, particularly in patients with low ATM protein levels 
• Future studies investigating therapies targeting DNA damage repair  in the 
maintenance setting, in Western patients and in combination with immunotherapy, 
chemotherapy, other targeted agents and radiotherapy will establish whether this 
approach has the potential to significantly improve outcomes in gastric cancer 
• The development of predictive signatures or biomarkers and means to overcome 
treatment resistance will prove vital to the success or otherwise of this approach  
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1. Introduction: Gastric Cancer and its current treatment 
As the 5th most common cancer and the 3rd leading cause of cancer related death in 2012 
gastric cancer remains a significant global health problem1. Despite modest improvements in 
overall survival over the last 4 decades the 5 year survival rate for gastric cancer remains low 
at 20%. Surgery provides the only curative treatment but two thirds of Western patients 
present with inoperable disease and, even with the addition of peri-operative therapy, the 
majority of patients treated with curative intent relapse within 5 years2,3. For patients with 
metastatic disease the prognosis is particularly bleak with median overall survival (mOS) of 3 
months with best supportive care (BSC) and under a year with 1st line combination 
chemotherapy4. 
In the advanced setting chemotherapy remains the cornerstone of treatment. If performance 
status allows, the 1st line standard of care consists of a backbone of a platinum and 
fluoropyrimidine with the addition of either an anthracycline or a taxane5,6. The genomic 
landscape of gastric cancer is highly complex and defining predictive biomarkers has been 
particularly difficult, hampering the use of targeted therapies. However, for the 20% of 
gastric cancer patients who are HER-2 positive, trastuzumab may now be added to the 
platinum/fluoropyrimidine backbone7 and ramucirumab, a vascular endothelial growth factor 
receptor 2 (VEGFR-2) inhibitor, may be considered in unselected patients as a single agent or 
in combination with paclitaxel in the second line setting8,9. In addition, apatanib, 
anotherVEGFR-2 inhibitor, has recently been reported to improve mOS in the third line 
setting in an Eastern population10. 
Worldwide second and even third line chemotherapy is increasingly used, with approximately 
half of patients who receive first line treatment being fit enough for second line treatment. 
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Weekly paclitaxel, docetaxel and irinotecan are all possible options but only improve mOS 
from approximately 3 months with BSC to between 4 and 5 months with chemotherapy11,12,13.  
Due to the limitations in current therapy for gastric cancer alternative strategies have been 
sought. Targeting damaged DNA repair is one such novel approach and is becoming an area 
of increased interest across multiple solid tumour types. 
2. DNA damage repair 
The human genome is constantly exposed to damage. This may be from endogenous factors 
such as oxidation, hydrolysis or alkylation of bases and errors in DNA replication or from 
exogenous factors including ultraviolet light, ionizing radiation and chemicals. The ability of 
the cell to repair this damage is vital for the maintenance of genomic integrity14. As such, 
organisms have evolved multiple pathways to repair DNA damage. Initially the cell must 
recognise the damaged DNA and activate the cell cycle checkpoints, to pause the cell cycle to 
allow the damage to be repaired. The repair pathway employed depends on the nature of the 
DNA damage. For single strand DNA damage the options include Mismatch Repair (MMR), 
Base Excision Repair (BER), Nucleotide Excision Repair (NER) and Direct Repair (DR) 
depending upon the type of damage present15,16,17, 18. If both DNA strands are severed, in a 
Double Strand Break (DSB), repair mechanisms used include Homologous Recombination 
(HR), classical or alternate Non- Homologous End Joining (NHEJ) and Single Strand 
Annealing (SSA)19,20,21. (Figure 1 and Table 1).  
Malfunctions of these repair pathways have varied deleterious consequences and are 
frequently associated with cancer (Table 2). Patients with Lynch Syndrome for example, have 
inactivating mutations in one or more MMR genes (MLH1, PMS2, MSH2 and MSH6) and are 
unable to correct errors in newly synthesized DNA. These errors often occur in repeated 
sequences known as microsatellites, which tend to be the same length throughout an 
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individual’s genome. Deficiency of MMR results in variations in theses microsatellites 
known as microsatellite instability (MSI), a mutator phenotype and a propensity for cancer, 
particularly colon, gastric and endometrial cancers. MSI is also seen in sporadic cancer where 
it is thought to be caused by epigenetic modulation of the MMR genes, usually through 
promoter hypermethylation22.  
Another cancer associated with faulty DNA repair is hereditary breast/ovarian cancer. Here 
patients have a germline mutation in the tumour suppressor genes BRCA1/2 and if they 
subsequently sustain a somatic mutation in the remaining wild type (WT) BRCA1/2 allele 
they lose BRCA1/2 protein function. Cells without intact BRCA1/2 are unable to repair DSB 
by HR as BRCA1/2 proteins are integral to this process23. The resulting HR deficiency 
(HRD) causes the cell to rely upon more error prone DNA repair mechanisms such as NHEJ 
with resulting genomic instability and oncogenesis. Although HRD is associated with the 
development of cancer it has also provided a novel approach to treating cancer, through 
exploiting synthetic lethality 24,25,26.  
3. Targeting Deficiencies in DNA Damage Repair 
3.1 Synthetic Lethality 
The concept of synthetic lethality describes a situation where 2 separate genetic mutations are 
relatively harmless when they occur individually but lethal if they occur in combination. 
Utilising synthetic lethality is very appealing in cancer therapeutics, as targeting 1 such gene 
with a particular therapy in a patient whose tumour is known to already have a 2nd genetic 
mutation could result in tumour cell death with minimal toxicity to normal tissue, where cells 
do not carry the 2nd mutation. This theory has been elegantly validated in the treatment of 
BRCA1/2 mutant cancers with Poly (ADP-ribose) polymerase (PARP) inhibitors. 
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3.2 Poly(ADP-ribose) polymerase (PARP) inhibition 
The large PARP family of enzymes, particularly PARP1 and 2, has been implicated in a 
number of DNA repair mechanisms. PARP enzymes prevent the formation of DSB through 
their involvement in the repair of SSB in BER27. In addition PARP enzymes indirectly help 
repair DSB through their involvement in activating ataxia-telangiectasia mutation (ATM), 
involved in HR and in deactivating DNA-dependent protein kinase, involved in NHEJ28.  
PARP inhibitors were designed to competitively bind the NAD binding site of PARP 
enzymes and directly interfere with their DNA repair function. PARP inhibition therefore 
results in persistent DNA SSBs and subsequent stalling of DNA replication forks causing 
DSB formation. Employing the synthetic lethality concept, in normal cells such DSB would 
be repaired by HR but in patients with BRCA1/2 mutations, tumour cells would be deficient 
in HR making this impossible. Instead the tumour cells would have to resort to the non-
conservative repair mechanisms resulting in genomic instability and eventual cell death 
through apoptosis.  
In 2005 a phase I study of olaparib (AZD2281, Lynparza), a selective and potent PARP1/2 
inhibitor, in a population enriched for BRCA1/2 mutants confirmed this approach had merit29. 
In this proof of concept study 19 heavily pre-treated patients with BRCA1/2 mutations and 
breast, ovarian or prostate cancer demonstrated a disease control rate of 63% and an objective 
response rate of 47%. Further, observed toxicities were mild and, as predicted, there was no 
increase in toxicity in carriers of the BRCA1/2 mutations versus non carriers. An expansion 
cohort in BRCA1/2 mutant ovarian cancer patients revealed a significant association between 
clinical benefit rate with olaparib and platinum sensitivity (platinum-sensitive 69%, resistant 
45%, and refractory 23%)30. This has been attributed to the ability of platinum agents to stall 
replication forks through the formation of DNA cross-links, causing DNA damage which also 
requires repair by BRCA1/2 mediated HR. 
D
ow
nl
oa
de
d 
by
 [K
ate
 Y
ou
ng
] a
t 0
6:4
5 0
4 A
ug
us
t 2
01
6 
9 
 
Following on from these early trials, two phase II single agent olaparib studies demonstrated 
sustained responses in BRCA1/2 mutant breast and ovarian cancers with response rates of 
41% and 33% respectively31,32. A further phase II study of maintenance olaparib, following a 
response to platinum therapy in patients with familial or sporadic high grade serous ovarian 
cancer, failed to show a statistically significant  increase in overall survival but increased 
progression free survival by approximately 7 months in those patients with germline or 
sporadic BRCA1/2 mutations33, 34. 
Based on these results in December 2014, the US Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) both approved olaparib monotherapy for the 
maintenance treatment of women with BRCA1/2 mutant high grade serous ovarian cancer, 
fallopian tube or primary peritoneal cancer who have demonstrated a complete or partial 
response to platinum based chemotherapy. 
More recently, in January 2016, the FDA also granted olaparib Breakthrough Therapy 
designation (BTD) for the monotherapy treatment of BRCA1/2 or ATM mutated metastatic 
Castration Resistant Prostate Cancer (mCRPC) in patients who have received a prior taxane-
based chemotherapy and at least one newer hormonal agent (abiraterone or enzalutamide). 
This was based on the results of the phase II TOPARP study where olaparib monotherapy 
demonstrated a response rate of 88% in patients with mCRPC and defects in DNA repair 
genes35. In this study the investigators hypothesized that in addition to prostate cancer 
patients with BRCA2 defects, prostate cancer patients with mutations in other genes involved 
in DNA damage repair may also be sensitive to treatment with olaparib. Patients provided a 
baseline biopsy which was used to conduct exome and transcriptome sequencing to generate 
a biomarker suite including defects in BRCA1/2, ATM, Fanconi’s anaemia genes and 
CHEK2. This phenomenon, where patients have sporadic mutations in DNA damage repair 
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genes evoking a phenotype similar to that seen in germline BRCA1/2 mutation carriers, has 
previously been described as “BRCAness” or “BRCA-like” 36. 
4. BRCA-like 
The idea of a BRCA-like phenotype was first described over a decade ago to describe a group 
of patients who may benefit from PARP inhibition, in addition to BRCA1/2 mutation carriers, 
who had defects in DNA repair which were not attributable to germline BRCA1/2 mutations.  
Germline mutations in BRCA1/2 (gBRCAm) are uncommon events. Only 5-10% breast 
cancers37 and 10-15% ovarian cancers38 are caused by an inherited mutation, most commonly 
in BRCA1/2. BRCA mutations are also seen in up to 7% pancreatic cancers39 and 6% prostate 
cancers40 but have rarely been described in gastric cancer. 
If patients with alternative defects, germline or somatic, in the HR pathway genes could be 
identified, the scope for exploiting synthetic lethality through PARP inhibition or other 
means would be much wider, across multiple solid tumour types. To this end multiple groups 
have sought to establish deficiencies in HR present in different tumour types and to develop 
means of identifying patients with such deficiencies for treatment, suggesting various 
signatures of HRD. 
5. Identifying Homologous Recombination Deficiency (HRD) 
5.1 Gene Signatures 
One method to identify HRD is to select an appropriate gene suite and look for defects, as 
demonstrated in the TOPARP study35. With advances in our understanding of DNA damage 
repair, a large number of genes which are important in HR and associated with malignancy 
have been identified41. These include BRCA1/2, ATM, Ataxia telangiectasia and Rad3-related 
(ATR), RAD51, Meiotic recombination 11 homologue A (MRE11A), Nijmegen breakage 
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syndrome protein 1(NBS1), Checkpoint Kinase 1/2 (CHK1/2), Cyclin-dependent protein 
kinase 12 (CDK12) and the Fanconi’s anaemia gene family. Defects in other genes, distinct 
from those known to be intrinsically involved in HR, may also be important as predictive 
biomarkers for sensitivity to PARP inhibition such as PTEN42, ARID1A43 and p5344.  
Particular patterns of defects may be evident in different tumour types and much remains to 
be learnt about the importance of specific mutations within these genes, the significance of 
epigenetic modulation of these genes and the varying patterns of drug resistance which may 
develop depending on the genes involved.  
Ongoing improvements in the affordability and speed of next generation sequencing make 
this a potentially valid approach in the future. Alternatively at present immunohistochemistry 
may be used to detect silencing of critical genes if validated assays are available. 
5.2 Structural rearrangement signatures 
Structural rearrangement signatures, looking at genomic scars, have also been investigated. 
This approach utilises the observation that structural rearrangements associated with defects 
in HR may take particular patterns. One such pattern of rearrangement is a high level of 
genomic loss of heterozygosity (LOH). Preliminary results from the ARIEL2 study, a phase 2 
open label study of rucaparib in ovarian cancer, describe the use of single-nucleotide 
polymorphism (SNP) analysis to identify and quantify genomic LOH. Patients were divided 
into 3 groups based on this quantification and their BRCA status, BRCA mutant patients, 
BRCA wild-type (WT) patients with high LOH and BRCA WT patients with low LOH.  
Overall response rates to rucaparib in these 3 groups were 69%, 39%, and 11%, respectively, 
suggesting that high levels of genomic LOH may be used to identify a group of patients 
without BRCA mutations who may be more likely to respond to rucaparib45. This assay is 
currently being tested in the ARIEL3 study of rucaparib as switch maintenance following 
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platinum-based chemotherapy in patients with ovarian, primary peritoneal or fallopian tube 
cancer (NCT01968213). 
Another example is “signature 3”, a specific base-substitution signature seen in patients with 
germline or somatic BRCA mutant breast, ovarian and pancreatic cancers, described by 
Alexandrov et al in their analysis of 4,938,362 mutations from 7,042 cancers46. In this 
signature there are substantial numbers of deletions (of up to 50 base pairs in size) with 
overlapping microhomology at the breakpoint junctions. This pattern has been attributed to 
the use of error prone DNA repair pathways in the place of compromised HR. The 
investigators noted that signature 3 was seen in a number of patients who did not have BRCA 
mutations, suggesting the signature could be used to identify patients with alternative causes 
of HRD.  
5.3 Mutational Burden 
Perhaps a more straightforward approach would be to look at overall mutational burden 
within a tumour as a biomarker for being BRCA-like. High overall numbers of somatic 
exome mutations per genome have been demonstrated in BRCA1/2 mutant ovarian cancer and 
within these patients, higher mutational load is associated with improved progression-free 
survival (PFS) and overall survival (OS) with platinum based chemotherapy. Interestingly in 
a study by Birkbak et al. using data from The Cancer Genome Atlas (TCGA) a substantial 
number of patients with BRCA mutated ovarian cancer but with low mutational burdens 
experienced relatively poor treatment outcomes, similar to those seen in patients with WT 
BRCA47, suggesting knowledge of degree of a patient’s mutational burden may be useful 
additional information when selecting treatment. 
5.4 Transcriptional Signatures 
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As an alternative to investigating specific genomic defects or scars, transcriptional signatures 
of BRCAness have been derived, describing gene expression profiles using microarrays. In 
epithelial ovarian cancer, for example, Konstantinopoulos et al. used a publically available 
microarray dataset from patients with BRCA mutant and sporadic ovarian cancer to develop a 
60 gene BRCAness profile48. This was then applied to tumour samples from patients with 
gBRCAm and sporadic disease. In the gBRCAm samples the BRCAness profile accurately 
distinguished between platinum sensitivity and resistance and in two patients the profile 
dynamically tracked the development of platinum resistance during treatment, associated 
with a return to functional BRCA1. Further, in the sporadic samples those patients with a 
BRCA-like profile had a better prognosis than those with a non-BRCA-like profile (overall 
survival 72 months vs. 41 months; log-rank P = 0.006). The investigators explained that they 
chose microarray gene expression profiling to develop a signature due to this technique 
having a broad based, non-mechanistic approach. They postulated this would have the highest 
chance of identifying the maximum number of patients with a BRCA-like phenotype, as this 
phenotype could have developed in a multitude of ways. 
5.5 Proteomics 
Moving downstream from a transcriptional signature, proteomics have also been considered.  
Proteomics analyses on RNAi knockdown breast cancer cell lines for key HR genes using 2 
dimensional-difference gel electrophoresis identified 308 significant protein changes in 
pathways associated with cell death, post‐translational modification and protein folding49. 
Exploratory proteomics analysis in an early phase study of olaparib and carboplatin in 
BRCA1/2 mutated breast and ovarian cancer described eight proteins whose levels correlated 
with response to treatment. Differences in levels of pS209-eIF4E and FOXO3a statistically 
significantly contributed to a linear model predicting response duration, with FOXO3a 
staining being the more reproducible50. FOXO3a promotes phosphorylation of ATM and 
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activates ATM mediated apoptosis in response to DNA damage. This data requires 
prospective validation but theoretically the use of a simple IHC assay as a predictive 
biomarker is certainly appealing.  
5.6 Functional assays 
A different approach to developing signatures to determine the presence or absence of genes 
or proteins important in HR is to look at the ability of the cell to actually perform HR. 
However, developing a clinically relevant assay has been fraught with difficulty as DNA 
damage repair pathways are dynamic processes, requiring DNA damage for activation and as 
such are difficult to measure in pre-treatment biopsy samples. 
One approach has been to look at RAD51 based functional assays, using 
immunohistochemistry to determine RAD51 nuclear localisation. RAD51 is an important 
DNA repair protein which is recruited to sites of DNA damage where it forms distinct 
nuclear foci when HR is active. The degree of foci formation can indicate if a cell is 
proficient in HR.51 This technique is successful in vitro when cells are exposed to DNA 
damage and a number of groups have developed ex-vivo protocols where a RAD51 response 
is elicited by DNA damage to a fresh biopsy sample, using radiation52 or the PARP inhibitor 
rucaparib53. It remains to be seen whether such an approach could realistically be transferred 
to the clinic. 
 
At present all of the approaches to detect HRD listed above require substantial refinement 
and validation before being implemented in the clinic. What is clear is that a small but 
significant proportion of multiple tumour types may exhibit HRD or BRCA-like 
D
ow
nl
oa
de
d 
by
 [K
ate
 Y
ou
ng
] a
t 0
6:4
5 0
4 A
ug
us
t 2
01
6 
15 
 
characteristics even if we do not yet know how best to define these subgroups. Gastric cancer 
has recently been identified as a tumour type with such an HR deficient subgroup. 
6. Homologous Recombination Deficiency in Gastric Cancer 
Interest in targeting HRD in gastric cancer was generated when gastric cancer cell lines were 
found to be particularly sensitive to single agent olaparib treatment (IC50 <500nM vs.1300nM 
for ovarian cancer cell lines). This sensitivity was attributed to deficiencies in HR54 and here 
ATM appears to play a key role.  
6.1 ATM deficiency in gastric cancer 
ATM, the tumour suppressor gene found on human chromosome 11q22-23 and mutated in the 
disorder Ataxia Telangiectasia, encodes a large multifunctional protein kinase (370kDa) 55. 
This protein kinase is important in the cellular response to DNA DSBs, inducing cell cycle 
arrest via p53 and facilitating repair through the phosphorylation of numerous downstream 
targets56. 
In gastric adenocarcinoma, ATM mutation and ATM protein loss have been associated with 
older patients, distal tumours, larger tumours, and tumours of intestinal histological type57. 
Low levels of phosphorylated ATM have been correlated with a poor prognosis, as well as 
with poorly differentiated histology and lymph node metastases58.  
It has been established that low levels of ATM, assessed by IHC, correlate with gastric cancer 
cell line sensitivity to olaparib59. This sensitivity appears to be further heightened by co-
existent p53 deficiency60. However, as p53 alterations are seen more commonly in proximal 
tumours61 in chromosomal unstable gastric cancers62 and ATM alterations are found more 
often in distal tumours and in microsatellite unstable tumours there may be relatively few 
patients where co-alterations exist. 
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Mutations in ATM are relatively infrequent events in gastric cancer, with only approximately 
10-15% patients’ tumour samples having an alteration in ATM 58,63. Germline ATM 
mutations are even rarer, found in only 2.7% gastric cancer patients64. ATM is a very large 
gene (66 exons spanning 150kb of genomic DNA) and there appear to be no particular 
mutational hot-spots, with the majority of the described alterations being single point 
mutations58,63.  
Despite this low frequency of ATM mutation, a comparatively high percentage of gastric 
tumour samples have been reported to have low ATM protein levels, between 21% and 65% 
in Eastern patients65,58. The causes of low ATM have not been fully elucidated but may 
include point mutations, epigenetic silencing, microRNA expression or intronic mutations 
associated with MSI57,60. In fact, in patients with gastric cancer and the MSI phenotype 
nearly 70% have an ATM intron mutation and over 50% have ATM protein loss57. It has been 
suggested that DNA repair genes may be a critical target for deficient MMR and MSI is seen 
in 15-30% of gastric cancers.  
Based on the above observations, Study 39 (NCT01063517), a double-blind phase II study of 
paclitaxel/ olaparib versus paclitaxel/placebo in the second line treatment of advanced gastric 
adenocarcinoma, was conducted66. 124 patients were randomised to receive paclitaxel (80 
mg/m2 intravenously on days 1, 8, and 15 of every 28-day cycle) with olaparib (100mg twice 
a day continuously) or matched placebo, followed by maintenance monotherapy with 
olaparib (200mg twice a day) or placebo.  
ATM status was assessed with a validated IHC assay, chosen as it demonstrated clear results 
with nuclear staining, and patients with low or undetectable levels of ATM protein were 
classified as ATMlow. Within this study only 14% of all patients screened were defined as 
D
ow
nl
oa
de
d 
by
 [K
ate
 Y
ou
ng
] a
t 0
6:4
5 0
4 A
ug
us
t 2
01
6 
17 
 
ATMlow but through patient selection the trial population was enriched such that 50% of the 
patients within the study were ATMlow.  
The study did not meet its primary endpoint of improved progression free survival (PFS) with 
the addition of olaparib, although there was a trend towards improvement, particularly in the 
ATMlow group (median PFS 5.29 vs. 3.68 months, HR= 0.74). However, overall survival 
(OS) was significantly increased in both the overall population (median OS 13.1 vs. 8.3 
months, HR= 0.56, 80% CI 0.41-0.75, p=0.005) and in the ATMlow group (median OS not 
reached vs. 8.2 months, HR =0.35, 80% CI 0.22-0.56, p=0.002).  
The treatment with olaparib and paclitaxel was well tolerated with a safety profile consistent 
with the published literature. Neutropaenia was the most common grade 3/4 adverse event 
(56% paclitaxel/olaparib vs. 39% paclitaxel/placebo), although rates of febrile neutropaenia 
were low. 
The investigators suggested a number of possibilities for the discrepancy between the OS and 
PFS results including the small sample size, a possible lack of correlation between PFS and 
OS, the effects of olaparib on long term colony formation or a post progression synergism of 
olaparib with irinotecan treatment66. The results from the follow on phase III GOLD study 
(NCT01924533), which has recently completed recruitment, are awaited and if the survival 
signal from study 39 is confirmed the results may be practice changing. 
6.2 Alternative sources of HRD in gastric cancer 
Although much has been made of the role of ATM loss leading to HRD in gastric cancer, as 
in other solid tumours, the full picture is no doubt more complicated and other HR factors 
may also be involved. 
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Using genomics data from the C.Bioportal67,68 it is evident that many of the other genes 
involved in HR are also altered in gastric cancer, albeit at low frequencies (Figure 2 and 
Table 3). As with ATM deficiency, epigenetics and microRNA involvement may also result 
in reduced expression of these genes even if they are not mutated. It will be important to look 
in depth at the significance of mutations in these genes versus other causes of loss of 
expression. Considering hypermethylation in particular, it has been suggested that resistance 
to treatment may occur more quickly in patients with promoter hypermethylation rather than 
gene mutation as treatment may trigger promoter demethylation and reactivation of the gene 
in question41. This idea is supported by data from a study of ovarian cancer patients looking 
at BRCA1 promoter hypermethylation. The 15% of patients who had BRCA1 promoter 
hypermethylation had an earlier onset of disease but had no better survival with platinum 
based chemotherapy than the remaining patients with intact BRCA1 expression69.  
Translational work in progress within Study 39 and GOLD will hopefully provide further 
insights into causes of HRD in gastric cancer and may enable the development of specific 
multi-gene signatures for HRD in this tumour type, in addition to simply looking at low ATM 
protein expression. 
One signature already in existence for HRD in gastric cancer is signature 3, the base-
substitution signature described above, previously seen in BRCA mutated breast, ovarian and 
pancreatic cancer.  A recent study where signature 3 was applied across 33 other tumour 
types demonstrated the  presence of signature 3 in 12% gastric cancers but not in any other 
tumour type70. Further studies are required to generate clinical data on the presence of 
signature 3 and response to PARP inhibition or platinum treatment in gastric cancer. 
 
7. Future Studies targeting faulty DNA damage repair in Gastric Cancer 
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The current interest in targeting HRD across various solid tumours has resulted in a multitude 
of clinical studies, many including patients with gastric cancer, a few of which we will 
highlight here.  
 
The above mentioned GOLD study, a phase III study of olaparib in combination with 
paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced 
gastric cancer who have progressed following first-line therapy, is expected to report in 2016 
and the results have the potential to significantly impact this field.  Patients in the GOLD 
study are from China, Japan, Korea and Taiwan. As recent clinical trials in oesophagogastric 
cancer have highlighted significant geographical variation in treatment response and 
outcomes, the OPERa study (EUDRACT: 2015-001605-14), currently in setup, will establish 
the frequency and significance of ATM alterations, other potential HRD signatures and 
PARP inhibition as a therapeutic strategy in gastric cancer in Western patients in the UK and 
Portugal, as much of the ATM data discussed above is from studies in Eastern patients.  
As successfully demonstrated in ovarian cancer, the role of maintenance PARP inhibition, in 
the form of rucaparib, is to be investigated in gastric cancer in one of the arms of the UK 
PLATFORM study71 (EUDRACT: 2014-002169-30).   
 
In light of the current excitement over the potential of immunotherapy in gastric cancer72 and 
elsewhere it is unsurprising that combining immunotherapy with agents targeting DNA 
damage repair is being considered. This has a sound biological rationale as a link has been 
established between HRD and increased immunogenicity in high grade serous ovarian cancer, 
with increased recruitment of tumour infiltrating lymphocytes, possibly due to hypermutated 
tumours harbouring high numbers of neoantigens73.  In gastric cancer the link between MSI 
and ATM deficiency may also be important, as in colorectal cancer it has been demonstrated 
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that tumours with MMR defects are particularly susceptible to immune checkpoint 
blockade74.  
 
Another biologically sound approach is to combine radiotherapy with agents targeting DNA 
damage repair deficiencies as DNA DSBs represent the most biologically significant lesions 
induced by radiotherapy treatment and deficiencies in DSB repair lead to increased radiation 
sensitivity75.  Trials in progress include the phase I PATRIOT study (NCT02223923) 
combining the ATR inhibitor AZD6738 with radiotherapy in solid tumours and the phase I 
ROCOCO (NCT 01460888) combining olaparib with radiotherapy in oesophageal 
adenocarcinoma or squamous carcinoma.  
 
Moving on from PARP inhibition, yet other studies are looking to target other aspects of 
DNA damage repair using agents such as AZD0156, an ATM kinase inhibitor (NCT 
02588105), AZD6738, an ATR inhibitor (NCT02264678) and AZD1775, a Wee1 inhibitor 
(NCT02511795). 
 
Such clinical studies will add to the growing knowledge base of how best to target DNA 
damage repair. The translational work being conducted alongside these studies will also 
provide important insights; hopefully generate predictive biomarkers and yield information 
regarding mechanisms of resistance to treatment and optimal treatment combination. 
 
8. Conclusion 
In the past few decades our understanding of the pathways involved in DNA damage repair 
has substantially improved. This knowledge has generated a novel treatment strategy for 
cancers, such as gastric cancer, where a subgroup of patients appears to have deficient DNA 
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damage repair. This strategy has so far shown some early promise in gastric cancer but there 
are many unanswered questions and this approach requires further significant investigation 
and validation. Nevertheless, in this poor prognosis disease novel therapies supported by a 
clear biological rationale should be welcomed and it will be exciting to see how this field 
continues to develop over the next decade. 
9. Expert Opinion  
Gastric cancer is a challenging malignancy to treat. The genomic landscape is complex with 
no clear molecular driver and useful predictive biomarkers, with the exception of HER2, have 
remained elusive. Current treatment options are limited and novel approaches keenly 
required.  
Targeting defective DNA damage repair in gastric cancer is appealing as a relatively 
substantial subgroup of patients may be suitable for such treatment, considering all of the 
various genetic alterations which may render a tumour sensitive. Establishing the significance 
of these gene alterations in gastric cancer and how best to define this sensitive subgroup 
remains a formidable task. We have discussed above the concern that hypermethylation of a 
gene’s promoter region may have a different significance to mutation of that same gene and 
there is also the issue of heterogeneity, already reported as a problem when considering ATM 
IHC between primary tumours and sites of metastasis65. In an ideal scenario patients would 
be identified using a gene signature, ideally from a peripheral blood sample, possibly using 
circulating tumour DNA. A similar method would then be used to monitor patients on 
treatment, looking for the emergence of resistance. Unfortunately it is likely to be some 
considerable time before such an approach is available in clinic. 
 
The ongoing translational work will provide key insights into the subtleties of DNA damage 
repair and its defects in gastric cancer and this will enable future rationale drug combinations 
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to increase efficacy and overcome resistance. As yet very little is known about resistance 
mechanisms to olaparib in gastric cancer where the HRD is caused by low ATM rather than 
defective BRCA1/2. Learning from the experience of PARP inhibition in ovarian cancer it 
seems likely that there will be multiple mechanisms, including secondary mutations and 
inactivation of other elements in the pathway to restore HR41, but again the translational work 
alongside the large clinical studies is of paramount importance. 
 
One treatment combination of particular interest is with immunotherapy. Immunotherapy 
represents a significant breakthrough in oncology and has shown promise in gastric cancer. 
One of the current challenges of immunotherapy is defining the patients who would most 
benefit from this approach and maximising the efficacy of treatment within those patients. 
The observation that HRD in ovarian cancer may result in increased numbers of tumour 
specific neoantigens, high numbers of CD8 +ve tumour infiltrating T cells and increased 
immunogenicity73 is exciting and certainly warrants investigation in HRD gastric cancer. 
Various early phase clinical trials investigating the combination of immunotherapy and a 
drug targeting deficient DNA damage repair are underway and will hopefully continue to 
evolve the field. 
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Key Phrases in DNA repair (Glossary Box) 
Synthetic lethality: Synthetic lethality refers to a situation where defects in 2 particular 
genes in combination are lethal but where each mutation on its own is compatible with 
viability. It is a concept exploited in cancer treatment with a view to sparing normal cells by 
targeting a cancer specific mutation. 
Microsatellite Instability (MSI): MSI is characterised by the presence of variable lengths of 
short nucleotide repeats, microsatellites, in tumour DNA. Three levels of MSI are usually 
described- MSI high, MSI low and MSI stable. MSI is caused by defects in the MMR genes 
or in their transcription. 
Chromosomal instability (CIN): CIN is characterised by abnormal numbers of 
chromosomes (copy number alterations, CNAs) and alterations in particular chromosomal 
regions (such as gene deletions, amplifications and loss of heterozygosity). These changes 
may result in oncogene activation and/ or loss of tumour suppressor gene function.  
Genomic Instability: An almost ubiquitous characteristic of cancer (either through deficient 
repair or due to defects which drive the accumulation of mutations). Genomic instability 
includes chromosomal instability, microsatellite instability and other forms of instability 
characterized by increased numbers of base-pair mutations. 
Western and Eastern: In this review these terms refer to patients of different ethnicities with 
Western patients coming from Europe, the Americas and Oceania and Eastern patients 
coming from Asia. 
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Type of DNA 
damage 
Repair 
Mechanism 
Description 
 
Key genes 
 
Single Strand 
Break 
Mismatch Repair 
(MMR) 
MMR enzymes monitor recently synthesized 
DNA to detect and repair errors in copied DNA 
sequences (A-G or T-C mismatch), especially 
within repeated sequences called 
microsatellites. 
MSH2 
MLH1 
MSH6  
PMS2  
 
 Base Excision 
Repair (BER) 
BER repairs simple DNA base lesions which do 
not distort DNA’s helix structure, usually caused 
by endogenous damage.  
MUTYH 
 
 Nucleotide 
Excision Repair 
(NER) 
NER repairs bulky DNA lesions which distort 
DNA’s helix structure, usually caused by 
exogenous damage.  
XP genes 
 Direct Repair (DR) DR involves the direct chemical reversal of a 
damaged base without excision or de novo 
synthesis 
MGMT 
Double Strand 
Break 
Homologous 
Recombination 
(HR) 
Preferred highly conserved, error free repair 
pathway. Active during S and G2 phase of the 
cell cycle. Here the undamaged sister chromatid 
is used as a homologous template to guide 
accurate repair. In addition to repairing DSB 
also involved in the repair of lesions which stall 
DNA replication forks. 
BRCA 1/2 
ATM  
ATR  
Fanconi Anaemia 
genes 
MRE11 
RAD51 
CHK1/2 
 Non-homologous 
end joining 
(NHEJ) 
Rapid error prone pathway which is cell cycle 
independent and may lead to genomic 
instability. Here there is no homologous 
template. NHEJ can be divided into classical and 
alternative NHEJ which is associated with 
XRCC 5/6 
PRKDC 
DCLRE1C 
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Table 1: Types of DNA damage and repair 
 
MSH2, mutS homolog 2; MLH1, mutL homolog 1; MSH6, mutS homolog 6; PMS2, PMS1 homolog 2 
mismatch repair system component;  MUYTH, MutY DNA glycosylase; XP, xeroderma pigmentosum; 
MGMT, O6-methylguanine DNA methyltransferase; BRCA 1/2, Breast Cancer 1/2; ATM, Ataxia 
telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; MRE11, Meiotic recombination 
11 homolog; CHK1, Checkpoint Kinase 1; XRCC 5/6, X-ray Repair complementing defect gene; PRKDC, 
protein kinase DNA activated catalytic polypeptide; DCLRE1C, DNA cross-link repair 1C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
insertions and deletions. 
 Single strand 
annealing (SSA) 
Error prone pathway which repairs breaks 
between two repeat sequences. Here the 
repeat sequence is used as a template to guide 
repair but deletions result in the loss of genetic 
material. 
RAD52 
RAD59 
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Table 2: Syndromes associated with faulty DNA damage repair 
HNPCC, Hereditary Non Polyposis Colon Cancer; LIG4, DNA ligase 4; SCID, severe combined 
immunodeficiency; XRCC4, X-ray Repair complementing defect gene 
 
 
 
 
 
 
 
 
DNA Repair 
Mechanism 
Consequence of loss of function  
 
Syndrome/ Associated Cancers 
Mismatch Repair 
(MMR) 
Microsatellite instability (MSI) Lynch Syndrome (HNPCC)- colon, 
endometrial, ovarian, gastric, urinary tract 
cancers 
Base Excision Repair 
(BER) 
Single strand breaks resulting in 
double strand breaks 
 
Loss may be embryonically lethal 
MUTYH mutation associated with colon 
cancer 
Nucleotide Excision 
Repair (NER) 
C to T mutations Xeroderma pigmentosum (XP)- skin cancer 
Homologous 
Recombination (HR) 
Error prone DNA repair and failure of 
chromosome segregation at meiosis 
Hereditary breast/ovarian/pancreatic 
cancer 
Ataxia Telangiectasia- leukaemia, 
lymphoma 
Non-homologous end 
joining (NHEJ) 
Error prone DNA repair as reliant upon 
alternative NHEJ such as 
microhomology mediated end joining 
(MMEJ) 
LIG4 syndrome- leukaemia 
XLF-SCID syndrome 
XRCC4 defect embryonically lethal 
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Table 3: Genetic alterations associated with HRD in gastric cancer 
Gene Frequency  of gene alteration* 
 
ATM 4.5-12.5% 
ATR 3.8-6.6% 
BRCA1 2-9.1% 
BRCA2 5.1-13.6% 
CDK12 2.6-14.6% 
PALB2 1-3.8% 
NBS1 (NBN) 2-7% 
MRE11A 1-9.4% 
 
ATM- ataxia telangiectasia mutated, ATR- ataxia telangiectasia and Rad3-related, CDK12- cyclin 
dependent kinase12, PALB2- partner and localiser of BRCA2, NSB1- Nijmegen breakage syndrome 1 
*Percentages quoted from c Bioportal for cancer genomics66,67 
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Figure 1: DNA Damage Repair Pathways 
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Figure 2. Cross-cancer alteration summary for ATM, ATR, BRCA1, BRCA2, CHEK1, CHEK2, FANCF, 
MDC1, MLH1, MSH2, PARP1, RAD51 (5 stomach adenocarcinoma studies / 12 genes) 
Percentages quoted from c Bioportal for cancer genomics66,67 
[Note the data from the UTokyo group was excluded as this only included patients with diffuse 
type gastric adenocarcinoma] 
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